Oesophageal Disorders — DCE Clinical Case

Focused history — what you must establish

• The discriminating dysphagia history: solids first or liquids from the start; progressive or intermittent; localisation; regurgitation character (acidic versus bland undigested food); odynophagia as a separate symptom; and the tempo over weeks to months [1].
• Alarm inventory: weight loss and its amount, appetite, haematemesis or melaena, anaemia symptoms, voice change, persistent cough or aspiration episodes [1].
• Risk profile: smoking and alcohol (squamous risk), reflux duration and severity with central obesity (adenocarcinoma risk via Barrett's), prior caustic ingestion, achalasia history, and any prior endoscopy [2].
• The host for what may come: cardiorespiratory comorbidity, performance status and nutrition — the variables that decide whether neoadjuvant therapy and oesophagectomy are even on the table [3].
• The patient's frame: what he thinks is happening, what he fears, and who supports him — a five-month delay in presentation usually has a reason.

Examination priorities

There are no oesophageal findings below the neck — the examination is about sequelae and stage. Look for temporal wasting and cachexia; pallor; a left supraclavicular (Virchow) node and cervical lymphadenopathy; chest signs of aspiration; hepatomegaly suggesting metastases; epigastric tenderness or mass; and the stigmata of smoking and chronic liver disease. State explicitly that the abdominal examination is frequently normal and that its normality does not reassure you — the diagnosis is endoscopic [1].

Presentation template (deliver this to the examiner)

"Mr Doyle is a 63-year-old smoker with a five-month history of progressive dysphagia to solids, now encroaching on soft foods, with 8 kg of weight loss — a mechanical obstructive pattern with alarm features, for which oesophageal malignancy is the diagnosis to exclude. He has cardiorespiratory reserve that I would quantify, and his nutrition is already compromised. My plan is urgent endoscopy with biopsy, and — if malignancy is confirmed — layered staging with CT, PET-CT and endoscopic ultrasound, with early dietetic involvement and multidisciplinary review, because the curative pathway for locally advanced disease runs through neoadjuvant chemoradiotherapy then surgery." [1] [3]

Management — what you will actually do

1. Scope first, this week: urgent upper gastrointestinal endoscopy with biopsy of any lesion — alarm features mean no empirical PPI trial and no outpatient delay [1] [2].
2. Stage in layers if cancer is confirmed: CT neck/chest/abdomen for gross spread, PET-CT for occult distant disease, endoscopic ultrasound for T-depth and regional nodes in those who remain potentially resectable [3].
3. Treat to the stage: intramucosal disease is managed endoscopically; locally advanced disease in a fit patient receives CROSS neoadjuvant chemoradiotherapy — weekly carboplatin and paclitaxel for five weeks with 41.4 Gy — then oesophagectomy, which roughly doubled median survival in the trial and kept that benefit at ten years [3] [4].
4. Support in parallel: dietitian-led nutrition (including feeding access if dysphagia is near-complete), smoking cessation, anaemia workup, and honest early communication about what the staging will decide.
5. If the scope shows something else entirely: a peptic stricture earns dilation plus long-term PPI; a motility picture with liquids from the start would have redirected to manometry — but his pattern is mechanical until histology says otherwise [2] [5].

Probing questions

"Why did you not trial a proton pump inhibitor first?" — "Because he has alarm features — progressive dysphagia, weight loss and probable iron deficiency. Guidelines are explicit that alarm features bypass empirical therapy and mandate endoscopy; a PPI trial here is a delay dressed as management" [1] [2].

"The endoscopy shows a T3N1 junctional adenocarcinoma with no metastases on PET. What now?" — "Multidisciplinary review for curative-intent neoadjuvant therapy: CROSS chemoradiation then oesophagectomy for an oesophageal-type junctional tumour, with perioperative FLOT chemotherapy as the alternative frame for gastric-type junctional adenocarcinoma — the histology, node map and his fitness decide which protocol he follows. I would not offer surgery without the neoadjuvant phase in a fit patient with locally advanced disease" [3] [4].

"He asks whether the aching swallow means it has spread. What do you say?" — "That the ache tells us the swallowing passage is involved but not how far — that is precisely what the scans are for, and I would rather give him a staged answer than a guessed one. Then I would make sure his nutrition and his questions are managed while staging completes" [1].